[1] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华肝脏病杂志, 2022, 30(12):1309-1331.
[2] Hui Z, Yu W, Fuzhen W, et al. New progress in HBV control and the cascade of health care for people living with HBV in China: evidence from the fourth national serological survey, 2020[J]. Lancet Reg Health West Pac, 2024, 51:101193.
[3] European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L: EASL Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2025.
[4] Xie C, Lin B L, Gao Z L, et al. Peginterferon alpha-2b enhances HBsAg loss in nucleos(t)ide analogue-treated patients: findings from a large real-world study (Everest Project)[J]. APASL2025,Abstract (OP0368).
[5] Hou J, Zhang W, Xie Q, et al. Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B[J]. N Engl J Med, 2024, 391(22):2098-2109.
[6] Gane E J, Dunbar P R, Brooks A E,et al. Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression[J]. J Hepatol, 2023, 78(3):513-523.
[7] Moskophidis D, Lechner F, Pircher H, et al. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells[J]. Nature, 1993, 362(6422):758-761.
[8] Giles J R, Globig A M, Kaech S M, et al. CD8+ T cells in the cancer-immunity cycle[J]. Immunity, 2023, 56(10):2231-2253.
[9] Bosch M, Kallin N, Donakonda S, et al. A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection[J]. Nature, 2024, 631(8022):867-875.
[10] Fung S, Choi H S J, Gehring A, et al. Getting to HBV cure: the promising paths forward[J]. Hepatology, 2022, 76(1):233-250.
[11] Shechter O, Sausen D G, Dahari H, et al. Functional cure for hepatitis B virus: challenges and achievements[J]. Int J Mol Sci, 2025, 26(8).
[12] Su M, Ye T, Wu W, et al. Possibility of PD-1/PD-L1 inhibitors for the treatment of patients with chronic hepatitis B infection[J]. Dig Dis, 2024, 42(1):53-60.
[13] Gao Q, Zhu H, Dong L, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma[J]. Cell, 2019, 179(2):561-577 e522.
[14] 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J]. 中华肝脏病杂志, 2024, 32(7):581-630.
[15] Sangro B, Sarobe P, Hervas-Stubbs S, et al. Advances in immunotherapy for hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(8):525-543.
[16] Qin S, Chen Z, Fang W, et al. Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: a randomized, double-blind, phaseⅢ trial[J]. J Clin Oncol, 2023, 41(7):1434-1443.
[17] El-Khoueiry A B, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088):2492-2502.
[18] Llovet J M, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2022, 19(3):151-172.
[19] Llovet J M. Exploring a new pathway for biomarker-based approval of immunotherapies[J]. Nat Rev Clin Oncol, 2023, 20(5):279-280.
[20] Sonpavde G P, Grivas P, Lin Y,et al. Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials[J]. Future Oncol, 2021, 17(19):2545-2558.
[21] Johnson D B, Nebhan C A, Moslehi J J, et al. Immune-checkpoint inhibitors: long-term implications of toxicity[J]. Nat Rev Clin Oncol, 2022, 19(4):254-267.
[22] 曾海銮, 高鑫. 肿瘤免疫检查点抑制剂相关内分泌疾病[J]. 中国临床医学, 2019, 26(6):810-816.
[23] Fletcher K, Johnson D B. Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update[J]. J Immunother Cancer, 2024, 12(7).
[24] Kim H, Kim D W, Kim M, et al. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: multicenter, real-world data (KCSG LU20-11)[J]. Cancer, 2022, 128(4):778-787.
[25] Zeng Z, Shi F, Zhou L, et al. Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma[J]. PLoS One, 2011, 6(9):e23621.
[26] Allahmoradi E, Mohammadi R, Kheirandish Zarandi P, et al. The CD8+ T cell exhaustion mechanisms in chronic hepatitis B infection and immunotherapeutic strategies: a systematic review[J]. Expert Rev Clin Immunol, 2023, 19(6):671-688.
[27] Chuah S, Lee J, Song Y, et al. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma[J]. J Hepatol, 2022, 77(3):683-694.
[28] Mon H C, Lee P C, Hung Y P, et al. Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy[J]. J Hepatol, 2025, 82(1):51-61.
[29] Qian J, Xie Y, Mao Q, et al. A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally suppressed patients with chronic hepatitis B who are HBeAg-negative[J]. Hepatology, 2025, 81(4):1328-1342.
[30] Gane E, Verdon D J, Brooks A E, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study[J]. J Hepatol, 2019, 71(5):900-907.
[31] 鲁凤民, 于乐成, 高林, 等. HBeAg阴性慢性乙型肝炎患者停药后HBsAg可阴转:停药-治愈策略或许正在来临[J]. 中华医学杂志, 2022, 102(40):3160-3166.
[32] Gehring A J, Protzer U. Targeting innate and adaptive immune responses to cure chronic HBV infection[J]. Gastroenterology, 2019, 156(2):325-337.
[33] Utzschneider D T, Legat A, Fuertes Marraco S A, et al. T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion[J]. Nat Immunol, 2013, 14(6):603-610.
[34] Fisicaro P, Barili V, Rossi M, et al. Pathogenetic mechanisms of T cell dysfunction in chronic HBV infection and related therapeutic approaches[J]. Front Immunol, 2020, 11:849.
[35] Kahan S M, Wherry E J, Zajac A J. T cell exhaustion during persistent viral infections[J]. Virology, 2015, 479-480:180-193.
[36] Ferrando-Martinez S, Snell Bennett A, Lino E, et al. Functional exhaustion of HBV-specific CD8 T cells impedes PD-L1 blockade efficacy in chronic HBV infection[J]. Front Immunol, 2021, 12:648420.
[37] Hoogeveen R C, Robidoux M P, Schwarz T, et al. Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection[J]. Gut, 2019, 68(5):893-904.
[38] Schuch A, Salimi Alizei E, Heim K, et al. Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load[J]. Gut, 2019, 68(5):905-915.
[39] Cheng Y, Zhu Y O, Becht E, et al. Multifactorial heterogeneity of virus-specific T cells and association with the progression of human chronic hepatitis B infection[J]. Sci Immunol , 2019, 4(32).
[40] Benechet A P, De Simone G, Di Lucia P, et al. Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming[J]. Nature, 2019, 574(7777):200-205.
[41] Andreata F, Laura C, Rava M, et al. Therapeutic potential of co-signaling receptor modulation in hepatitis B[J]. Cell, 2024, 187(15):4078-4094 e4021.
[42] Rivino L, Le Bert N, Gill U S, et al. Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation[J]. J Clin Invest, 2018, 128(2):668-681.
[43] Pallett L J, Davies J, Colbeck E J, et al. IL-2(high) tissue-resident T cells in the human liver: sentinels for hepatotropic infection[J]. J Exp Med, 2017, 214(6):1567-1580.
[44] Wu L, Deng H, Feng X, ,et al. Interferon-gamma(+) Th1 activates intrahepatic resident memory T cells to promote HBsAg loss by inducing M1 macrophage polarization[J]. J Med Virol, 2024, 96(5):e29627.
[45] Odorizzi P M, Pauken K E, Paley M A, et al. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells[J]. J Exp Med, 2015, 212(7):1125-1137.
[46] Thimme R, Bertoletti A, Iannacone M. Beyond exhaustion: the unique characteristics of CD8+ T cell dysfunction in chronic HBV infection[J]. Nat Rev Immunol, 2024, 24(11):775-776.
[47] Topalian S L, Hodi F S, Brahmer J R, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26):2443-2454.
[48] Zeng Y, Huang J, Pang J, et al. The occurrence of immune-related adverse events is an independent risk factor both for serum HBsAg increase and HBV reactivation in HBsAg-positive cancer patients receiving PD-1 inhibitor combinational therapy[J]. Front Immunol, 2024, 15:1330644. |
